Pharmacokinetic Considerations in the Treatment of Bacterial Keratitis

Clinical Pharmacokinetics

Volumn 27, Issue 2, 1994, Pages 129-149

  Callegan, Michelle C ^a   O’Callaghan, Richard J ^a,b   Hill, James M ^a,b,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c LSU EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BACTERIAL ENZYME; BACTERIAL TOXIN; CEFALOTIN; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; COLLAGEN; CYCLOPLEGIC AGENT; DEXAMETHASONE; FLURBIPROFEN; GENTAMICIN; LIDOCAINE; METHYLPREDNISOLONE; NAFCILLIN; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PENICILLIN G; PREDNISOLONE; TOBRAMYCIN; VANCOMYCIN;

ADJUVANT THERAPY; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AQUEOUS HUMOR; BACTERIAL INFECTION; CLINICAL TRIAL; CORNEA; CORNEA INJURY; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG PENETRATION; ELECTRIC CURRENT; EYE INJURY; HOST RESISTANCE; HUMAN; IONTOPHORESIS; KERATITIS; META ANALYSIS; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SCAR FORMATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUBCONJUNCTIVAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; UVEITIS;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS; COLLAGEN; DRUG CARRIERS; DRUG RESISTANCE, MICROBIAL; EYE INFECTIONS, BACTERIAL; HUMAN; IONTOPHORESIS; KERATITIS; OPHTHALMIC SOLUTIONS; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028094448     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199427020-00005     Document Type: Review

References (180)

1. Tear break-up time is related to blink frequency
2. Damage of outer membrane of enteric Gram-negative bacteria by lactoferrin and transferrin
3. Influence of lysozyme on aggregation of Staphylococcus aureus
4. Serum and tear immunoglobulins in bacterial, fungal and viral corneal ulcers
5. Basic ocular immunology
6. Alternate and classical pathway components of complement in the normal cornea
7. Structure and function of the cornea
8. Bacterial and fungal keratitis
9. Contact lens-related infectious keratitis
10. The ocular response to contact lens wear
11. The effects of extended-wear hydrophilic contact lenses on the human corneal epithelium
12. Antibacterial agents in the treatment of ocular infections
13. Anatomical barriers for antimicrobial agents
14. Ulcerative keratitis associated with contact lens wear
15. Microbiology of contact lens-related keratitis
16. Infectious keratitis in Baltimore
17. Ulcerative keratitis: survey of 30 years’ laboratory experience
18. Spectrum of microbial keratitis in south Florida
19. Microbial keratitis in childhood
20. Microbial keratitis in children
21. Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal
22. Corneal ulceration at an urban African hospital
23. Corneal ulcer disease in Bangladesh
24. Analysis of adhesion, piliation, protease production and ocular infectivity of several P. aeruginosa strains
25. Adherence of Staphylococcus aureus to rabbit corneal epithelial cells
26. Characterization of pseudomonal adherence to unwounded cornea
27. An organ culture system for study of adherence of Pseudomonas aeruginosa to normal and wounded corneas
28. Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis
29. Probing Pseudomonas aeruginosa, an opportunistic pathogen
30. The role of pneumolysin in ocular infections with Streptococcus pneumoniae
31. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis
32. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: Therapy with ciprofloxacin, vancomycin and cefazolin
33. Genetic analysis of extracellular toxins of Staphylococcus aureus
34. Pseudomonas aeruginosa ocular infections
35. Therapeutic review: tobramycin in ophthalmology
36. Pseudomonas aeruginosa invades into and survives inside cells during corneal infection
37. Pseudomonas aeruginosa protease IV: Cloning of a caseinase which is not transcriptionally activated by lasR
38. Corneal virulence of Pseudomonas mutants deficient in specific exoproteins
39. A review of bacterial keratitis and bacterial conjunctivitis
40. Confirmation of the role of pneumolysin in ocular infections with Streptococcus pneumoniae
41. Polymorphonuclear leukocyte kinetics in experimentally induced keratitis
42. Relevance of host-derived and bacterial factors in Pseudomonas aeruginosa corneal infections
43. Tissue destruction by neutrophils
44. Experimental Pseudomonas keratitis
45. Experimental bacterial keratitis in neutropenic guinea pigs: Polymorphonuclear leucocytes in corneal host defense
46. Pseudomonas aeruginosa keratitis in leukopenic rabbits
47. Inhibition of matrix-degrading metalloproteinases in corneal ulceration
48. Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodelling cornea
49. Proteolytic activation of corneal matrix metalloproteinase by Pseudomonas aeruginosa elastase
50. Collagen shields for ocular drug delivery
51. Collagen shields
52. Ocular iontophoresis
53. Therapy for ocular bacterial infection
54. Topical vs subconjunctival treatment of bacterial corneal ulcers
55. Ocular penetration of antibiotics
56. Corneal ulcers in patients with cosmetic extended-wear contact lenses
57. Corneal ulcers associated with extended-wear soft contact lenses
58. Penetration of anti-staphylococcal antibiotics into the human eye
59. Current therapy for bacterial keratitis and bacterial conjunctivitis
60. Update on the medical management of corneal and external eye diseases, corneal transplantation, and keratorefractive surgery
61. Topical vs systemic gentamicin penetration into the human cornea and aqueous humor
62. Levels of vancomycin in aqueous humor after topical eye drops administration
63. Ofloxacin vs tobramycin for the treatment of external ocular infection
64. Topical ofloxacin compared with gentamicin in the treatment of external ocular infection
65. Successful treatment of methicillin-resistant Staphylococcus aureus keratitis with topical ciprofloxacin
66. Safety and efficacy of topical norfloxacin versus tobramycin in the treatment of external ocular infections
67. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis
68. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis
69. Corneal stromal penetration of topical ciprofloxacin in humans
70. Corneal tissue levels of topically applied ciprofloxacin
71. Intraocular penetration of topically applied fluoroquinolone antibiotics into aqueous humor
72. The successful treatment of bacterial corneal ulcers with ciprofloxacin ointment
73. Topical fluoroquinolones: Antimicrobial activity and in vitro corneal epithelial toxicity
74. Staphylococcal keratitis: Experimental model in guinea pigs
75. Tobramycin iontophoresis into corneas infected with drug-resistant Pseudomonas aeruginosa
76. Quantitation of bacterial infection and antibiotic effect in the cornea
77. Topical antibiotic therapy of staphylococcal keratitis
78. Pathogenesis of experimental Pseudomonas keratitis in the guinea pig: Bacteriologic, clinical, and microscopic observations
79. Experimental Pseudomonas keratitis in the rabbit: bacteriologic, clinical, and microscopic observations
80. Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits
81. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis
82. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis
83. Loading doses and extended dosing intervals in topical gentamicin therapy
84. Penetration of norfloxacin into the aqueous humor of the human eye
85. Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model
86. Collagen shield delivery versus topical drop administration of tobramycin against Staphylococcus aureus keratitis in the rabbit
87. A rat model of bacterial keratitis: Effect of antibiotics and corticosteroid
88. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis
89. Pseudomonas aeruginosa
90. Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit
91. Ciprofloxacin ointment versus ciprofloxacin drops for the therapy of experimental Pseudomonas keratitis
92. Treatment of experimental Pseudomonas corneal ulcers with enoxacin, a quinolone antibiotic
93. The fluoroquinolones: New antibiotics in ophthalmology
94. Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections
95. The quinolones
96. Microbiologic aspects of fluoroquinolones
97. Efficacy and ocular penetration of Sparfloxacin in experimental streptococcal endophthalmitis
98. Effect of the abscess environment on the antimicrobial activity of ciprofloxacin
99. Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: Evidence for resistance to ‘late’ treatment of infections
100. Ciprofloxacin: In vitro activity, mechanism of action, and resistance
101. The successful treatment of bacterial corneal ulcers with ciprofloxacin
102. Gentamicin resistance in staphylococcal corneal ulcers
103. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus
104. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis
105. The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital
106. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: Clinical significance and therapeutic approaches
107. Bacterial antibiotic resistance before and after clinical application in the United States
108. Rapid development of Ciprofloxacin resistance in methicillin susceptible and resistant Staphylococcus aureus
109. Increasing resistance of Staphylococcus aureus to ciprofloxacin
110. Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada
111. Outer membrane changes in quinolone resistant Pseudomonas aeruginosa
112. Drug resistance in bacteria: History, genetics and biochemistry
113. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a veterans affairs medical center
114. Ciprofloxacin resistance among ocular staphylococcal and streptococcal isolates: Potential role of newer generation fluoroquinolones
115. Ciprofloxacin Staphylococcus aureus resistance
116. Topical vancomycin formulation for methicillin-resistant Staphylococcus epidermidis blepharoconjunctivitis
117. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium
118. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium
119. Emergence of drug-resistant pneumococci in the United States
120. High rate of penicillin-resistant Streptococcus pneumoniae
121. Recurrence of microbial keratitis concomitant with anti-inflammatory treatment in an animal model
122. Topical steroids in the treatment of central and paracentral corneal ulcers
123. Topical antiinflammatory agents in an animal model of microbial keratitis
124. Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis
125. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis
126. Topically administered corticosteroids: Effect on antibiotic-treated bacterial keratitis
127. Use of corticosteroids in the treatment of corneal inflammation
128. Ocular inflammation and antiinflammatory drugs
129. Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis
130. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease
131. Treatment of experimental Pseudomonas keratitis with cyclo-oxygenase and lipoxygenase inhibitors
132. The solubility of antibiotic and corticosteroid combinations
133. Selection of corticosteroids and antibiotics for collagen shields
134. Use of collagen shields as a surgical adjunct
135. Therapeutic applications of a collagen bandage lens: A preliminary report
136. The effect of collagen shields on epithelial wound healing in rabbits
137. Comprehensive conservative treatment of dystrophia endothelialis et epithelialis corneae, using a therapeutic collagen coating
138. Porcine collagen corneal shield treatment of persistent epithelial defects following penetrating keratoplasty
139. Guest editorial: Collagen shield symposium
140. Therapeutic and protective properties of the corneal collagen shield
141. The collagen shield as a collagenase inhibitor and clinical indicator of collagenase activity on the ocular surface
142. Collagen shields
143. New horizons in ocular drug delivery
144. Soluble gentamicin ophthalmic inserts as a drug delivery system
145. Collagen shield drug delivery: Therapeutic concentrations of tobramycin in the rabbit cornea and aqueous humor
146. Collagen-shield delivery of gentamicin and vancomycin
147. Noncross-linked collagen discs and cross-linked collagen shields in the delivery of gentamicin to rabbits eyes
148. Collagen shields impregnated with gentamicin-dexamethasone as a potential drug delivery device
149. Use of collagen corneal shields in the treatment of bacterial keratitis
150. Efficacy of tobramycin-soaked collagen shields vs tobramycin eyedrop loading dose for sustained treatment of experimental Pseudomonas aeruginosa-induced keratitis in rabbits
151. Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis
152. Treatment of experimental Pseudomonas keratitis using collagen shields containing tobramycin
153. Evaluation of corneal collagen shields as a drug delivery device for the treatment of experimental Pseudomonas keratitis
154. Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis
155. Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis
156. Iontophoresis of gentamicin into aphakic rabbit eyes: Sustained vitreal levels
157. A fresh look at iontophoresis
158. Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit
159. Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit
160. Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas
161. Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonal keratitis
162. Dexamethasone delivery by collagen corneal shields
163. Collagen shield enhancement of topical dexamethasone penetration
164. Collagen corneal shields enhance penetration of topical prednisolone acetate
165. Corneal toxicity with antibiotic steroid-soaked collagen shields
166. Delivery of fluorescein to the anterior chamber using the corneal collagen shield
167. Collagen shields: Efficacy, safety and comfort in the treatment of human traumatic corneal abrasion and effect on vision in healthy eyes
168. Management of epithelial and wound healing problems after penetrating keratoplasty
169. Clinical uses of collagen shields
170. Comparative study of a collagen shield and a subconjunctival injection at the end of cataract surgery
171. Collagen shield delivery of ciprofloxacin in uninflamed eyes
172. Transscleral and transcorneal iontophoresis of vancomycin in rabbit eyes
173. Iontophoresis
174. The flow of aqueous humor in the human eye
175. New methods of measuring the rate of aqueous flow in man with fluorescein
176. Iontophoresis for eyelid anesthesia
177. Iontophoretic local anesthesia for conjunctival surgery
178. Considerations on the use of corticoids by ionization in certain ocular diseases